Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02412735 · ClinicalTrials.gov registry record · Phase 3
Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
A Phase 3 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 3
- Development phase
- 404
- Enrollment target
NCT02412735 is a Phase 3 study that has completed, run by Mesoblast. The registered enrollment target is 404 participants.
The verdict
NCT02412735, a Phase 3 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 404 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in participants with chronic low back pain (\> 6 months) associated with moderate radiographic degenerative changes of a disc.
Interventions
- DRUG Placebo
- DRUG Rexlemestrocel-L
- DRUG Rexlemestrocel-L + HA Mixture
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2015-03-06 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02412735
The ClinicalTrials.gov registry entry for NCT02412735 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02412735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02412735 about?
NCT02412735 is a clinical study titled "Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain". This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the safety and efficacy of Mesoblast's rexlemestrocel-L alone or combined with hyaluronic acid (HA) in participants with chronic low back pain (\> 6 months) associated with moderate ra...
What is the current status of trial NCT02412735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 404 participants. The study started on 2015-03-06. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT02412735?
The interventions under investigation include: Placebo (DRUG), Rexlemestrocel-L (DRUG), Rexlemestrocel-L + HA Mixture (DRUG).
Who is sponsoring clinical trial NCT02412735?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.